Skip to main content
letter
. 2014 Jun 27;4(6):e224. doi: 10.1038/bcj.2014.44

Figure 1.

Figure 1

Overall survival (a) and duration of remission (b) for patients with BCP-ALL, overall T-ALL and the standard-risk subgroup of thymic T-ALL enrolled into GMALL trials.